Universitätsklinikum Ulm

Phosphosite Analysis of the Cytomegaloviral mRNA Export Factor pUL69 Reveals Serines with Critical Importance for Recruitment of Cellular Proteins Pin1 and UAP56/URH49 (2020) Thomas M, Müller R, Horn G, Bogdanow B, Imami K, Milbradt J, Steingruber M, et al. Journal article Personalising drug safety—results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED) (2020) Just KS, Dormann H, Böhme M, Schurig M, Schneider KL, Steffens M, Dunow S, et al. Journal article Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies (2020) Schneeweiss A, Hartkopf AD, Mueller V, Woeckel A, Lux MP, Janni W, Ettl J, et al. Journal article, Review article Predictive value of fibroblast growth factor receptor (FGFR) alterations on anti-PD-(L)1 treatment outcomes in patients (Pts) with advanced urothelial cancer (UC): Pooled analysis of real-world data (2020) Kim WY, Rose T, Roghmann F, Eckstein M, Jarczyk J, Zengerling F, Sikic D, et al. Conference contribution Association of KRT20 and KRT5 with response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Roghmann F, Reike M, Wirtz R, Kriegmair M, Erben P, Tully K, Weyerer V, et al. Conference contribution Smoking status and PD-L1 mRNA-expression as a predictor of response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer (2020) Reike M, Juette H, Wirtz R, Erben P, Tully K, Eckstein M, Weyerer V, et al. Conference contribution Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance (2020) Engel C, Fischer C, Zachariae S, Bucksch K, Rhiem K, Giesecke J, Herold N, et al. Journal article Exon-4 mutations in KRAS affect MEK/ERK and PI3K/AKT signaling in human multiple myeloma cell lines (2020) Weissbach S, Heredia-Guerrero SC, Barnsteiner S, Grosshans L, Bodem J, Starz H, Langer C, et al. Journal article Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG) (2020) Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, et al. Conference contribution Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution